Quantcast

Latest Anaplastic lymphoma kinase Stories

2014-01-29 13:16:56

A University of Colorado Cancer Center study published today in the International Journal of Radiation Oncology Biology and Physics shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease. Eliminating these pockets of resistant disease allows patients to continue treating the overall condition with crizotinib, leading to improved 2-year survival rates...

2013-12-18 11:26:28

A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients. “When you have known oncogenes that are already targeted by FDA-approved drugs, it just made sense...

2013-10-21 13:15:33

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. About 3 to 5 percent of lung cancers harbor ALK gene abnormalities. The drug crizotinib (Xalkori), which blocks ALK protein kinase activity,...

2013-09-10 23:02:58

A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. Aurora, Colo. (PRWEB) September 10, 2013 A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. The...

2013-06-25 19:17:47

Could be reliable and cost-effective diagnostic approach in lung cancer ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (NSCLC). It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma that can benefit by the treatment of ALK-inhibitors. Development of robust and reliable laboratory tests for predictive biomarkers is essential to select appropriate patients for targeted therapy....

2013-01-21 10:27:56

CHOP researcher leads large multicenter gene sequencing study of neuroblastoma An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutations–mutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now refocused on how neuroblastoma tumors evolve in response to...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related